Fig. 5: AREG level of expression correlates with amivantamab efficacy against EGFRWT NSCLC PDX models independent of amivantamab Fc function. | npj Precision Oncology

Fig. 5: AREG level of expression correlates with amivantamab efficacy against EGFRWT NSCLC PDX models independent of amivantamab Fc function.

From: Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression

Fig. 5: AREG level of expression correlates with amivantamab efficacy against EGFRWT NSCLC PDX models independent of amivantamab Fc function.The alternative text for this image may have been generated using AI.

A Ten EGFRWT NSCLC PDX models were established in mice and treated for 3-4 weeks twice a week with 10 mg/kg of either Isotype control, amivantamab, or IgG2σ. The ΔTGI (%) exerted by either amivantamab (blue) or IgG2σ (red) was calculated one week post treatment completion. IgG2σ was not evaluated in the LXFA-629 model. The ΔTGI induced by IgG2σ in the LXAA-SMTCA62 model was found to be a significant outlier and excluded from the analysis. Error bars represent the standard error of the mean. B Amivantamab (i) and IgG2σ (ii) ΔTGI (%) were determined against these NSCLC PDX models and plotted against EGFR ligand AREG RNA levels (transcripts per million, TPM) determined by RNAseq analysis. Spearman’s correlation were calculated for ligand: treatment relationship.

Back to article page